Eribulin Advanz Pharma

Eribulin Mesylate is a chemotherapy medication used to treat certain types of cancer. It works by slowing or stopping cancer cell growth, often prescribed for advanced breast cancer and liposarcoma.

Eribulin Mesylate is primarily used in the treatment of metastatic breast cancer and liposarcoma. It is a type of chemotherapy drug that targets cancer cells to inhibit their growth and spread. Patients typically receive this medication intravenously under medical supervision. The drug is often considered when other treatments have not been effective.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience peripheral neuropathy, which can cause numbness or tingling in the hands and feet. It is important to discuss any persistent or severe side effects with a healthcare provider.

Eribulin Mesylate should be handled with care and administered by a healthcare professional. It is important to follow all safety guidelines when using this medication. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment.

Eribulin Mesylate may interact with other medications, including those that affect liver function. It is important to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this drug.